Stock Watch: Pharma And Anti-Pharma

How Merck And Pfizer Polarized Second-Quarter Earnings

 
• By Andy Smith

While not direct competitors in all therapeutic areas, Pfizer’s and Merck’s sales offered some stark contrasts in the second quarter.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from Stock Watch

More from Business